GB202205161D0 - Nucleotide delivery of cancer therapy - Google Patents
Nucleotide delivery of cancer therapyInfo
- Publication number
- GB202205161D0 GB202205161D0 GBGB2205161.9A GB202205161A GB202205161D0 GB 202205161 D0 GB202205161 D0 GB 202205161D0 GB 202205161 A GB202205161 A GB 202205161A GB 202205161 D0 GB202205161 D0 GB 202205161D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- cancer therapy
- nucleotide delivery
- nucleotide
- delivery
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2205161.9A GB202205161D0 (en) | 2022-04-08 | 2022-04-08 | Nucleotide delivery of cancer therapy |
PCT/EP2023/054573 WO2023161350A1 (en) | 2022-02-24 | 2023-02-23 | Nucleotide delivery of cancer therapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2205161.9A GB202205161D0 (en) | 2022-04-08 | 2022-04-08 | Nucleotide delivery of cancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
GB202205161D0 true GB202205161D0 (en) | 2022-05-25 |
Family
ID=81653152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB2205161.9A Ceased GB202205161D0 (en) | 2022-02-24 | 2022-04-08 | Nucleotide delivery of cancer therapy |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB202205161D0 (en) |
-
2022
- 2022-04-08 GB GBGB2205161.9A patent/GB202205161D0/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4171548A4 (en) | Combination therapy for treatment of cancer | |
EP4010081A4 (en) | Combination therapy for treatment of cancer | |
GB202114972D0 (en) | Gene therapy | |
IL307964A (en) | Combination therapy for cancer treatment | |
GB202003618D0 (en) | Gene Therapy | |
GB202205161D0 (en) | Nucleotide delivery of cancer therapy | |
IL300171A (en) | Combined therapy against cancer | |
GB202003109D0 (en) | Gene therapy | |
GB202002202D0 (en) | Gene therapy | |
GB202215198D0 (en) | Gene therapy treatment | |
GB202318158D0 (en) | Cancer therapy | |
GB202302018D0 (en) | Cancer therapy | |
GB202218395D0 (en) | Cancer therapy | |
GB202212918D0 (en) | Cancer therapy | |
GB202316264D0 (en) | Gene therapy | |
GB202315668D0 (en) | Gene therapy | |
GB202214445D0 (en) | Gene therapy | |
GB202212092D0 (en) | Gene therapy | |
GB202206346D0 (en) | Gene therapy | |
AU2023901713A0 (en) | Targeted dual administration cancer therapy | |
IL312899A (en) | Combination therapy for treatment of cancer | |
IL300106A (en) | Combination therapy for treatment of cancer | |
GB202407048D0 (en) | Cancer therapy | |
GB202311976D0 (en) | Treatment of cancer | |
IL312026A (en) | Therapeutic rna for lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |